For US Healthcare Professionals

Contemplate more stringent goals in PsA

Striving for and achieving stringent disease outcome goals

Studies have shown that patients who achieve more stringent outcome goals, such as MDA and cDAPSA remission, are more likely to experience1,2:

GRAPPA and OMERACT guidelines recommend setting goals to achieve remission or low disease activity, with regular monitoring and assessment, for optimal patient outcomes in PsA.4,5

GRAPPA=Group for Research and Assessment of Psoriasis and Psoriatic Arthritis; OMERACT=Outcome Measures for Rheumatology Clinical Trials.

Does the mechanism of disease contribute to setting outcome goals?

Learn more about the mechanisms of disease in PsA to help inform disease management decisions and setting higher outcome goals.

Gaze upon the Gallery of Cytokines


Types of measures

Review the different disease outcome measures used to assess disease activity in patients with PsA.

Continue PsA tour Back to: Suboptimal disease outcomes


Suboptimal disease outcomes

Back to previous

  1. Coates LC, Orbai AM, Morita A, et al. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. BMC Rheumatol. 2018;2:24
  2. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3-17
  3. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res. 2010;62(7):965-969
  4. Coates LC, FitzGerald O, Merola JF, et al. Group for research and assessment of psoriasis and psoriatic arthritis/outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis. Arthritis Rheumatol. 2018;70(3):345-355
  5. Coates LC, Soriano ER, Corp N, et al. Group for research and assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-479